Affymetrix Inc (AFFX)

14.01
0.02 0.14
NASDAQ : Technology
Prev Close 13.99
Open 14.03
Day Low/High 14.00 / 14.05
52 Wk Low/High 8.28 / 16.15
Volume 5.03M
Avg Volume 3.49M
Exchange NASDAQ
Shares Outstanding 80.54M
Market Cap 1.13B
EPS 0.13
P/E Ratio 107.61
Div & Yield N.A. (N.A)

Affymetrix Delivers First Custom Axiom Array For Kaiser Permanente/UCSF Genotyping Project

Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has delivered the first custom array designed for a 100,000-sample genotyping project to be performed using the Axiom™ Genotyping Solution.

The Automated GeneTitan Instrument And Axiom Array Plates Enable Scientists To Process More Than 760 Samples Per Week. (Photo: Business Wire)

Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines.

Affymetrix To Webcast Presentation From Deutsche Bank Securities 35th Annual Health Care Conference

Affymetrix, Inc. (NASDAQ:AFFX) today announced the webcast of its presentation at the Deutsche Bank Securities 35 th Annual Health Care Conference in Boston.

Affymetrix Launches Axiom Genome-Wide ASI Array For Maximized Coverage Of East Asian Populations

Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Axiom™ Genome-Wide ASI Array, the first commercial product to provide maximum power for genome-wide association studies (GWAS) in East Asian ...

Affymetrix Inc. Q1 2010 Earnings Call Transcript

Affymetrix Inc. Q1 2010 Earnings Call Transcript

Affymetrix Reports First Quarter 2010 Results

Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the first quarter of 2010.

Affymetrix Launches DNA Copy Number Service For Difficult FFPE Samples In Cancer Research

Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples.

Affymetrix To Host Conference Call On April 21, 2010 To Announce First Quarter Results

Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will release operating results for the first quarter after close of the stock market on Wednesday, April 21, 2010.

Affymetrix And The Jackson Laboratory Launch First Genotyping Tool For Studying Mouse Strain Diversity

Affymetrix, Inc. (NASDAQ:AFFX) and The Jackson Laboratory today announced the full commercial launch of the Affymetrix® Mouse Diversity Genotyping Array.

Timothy Barabe Appointed Chief Financial Officer Of Affymetrix

Affymetrix, Inc. (NASDAQ:AFFX) today announced that Timothy Barabe has been appointed Executive Vice President and Chief Financial Officer of the company.

Affymetrix Appoints Jami Dover Nachtsheim And Nelson C. Chan To Board Of Directors

Affymetrix Appoints Jami Dover Nachtsheim And Nelson C. Chan To Board Of Directors

Affymetrix, Inc. (NASDAQ:AFFX) announced today that Jami Dover Nachtsheim and Nelson C.

Affymetrix To Webcast Presentations At Two Financial Conferences In March

Affymetrix To Webcast Presentations At Two Financial Conferences In March

Affymetrix, Inc. (NASDAQ:AFFX) today announced that company management will provide a corporate overview at two upcoming financial conferences.

Affymetrix Launches GeneAtlas™ Personal Microarray System For Whole-Genome Gene Expression

Affymetrix, Inc. (NASDAQ: AFFX) today announced the launch of the GeneAtlas™ System, a complete, personal solution for processing Affymetrix arrays and characterizing changes in gene expression in a variety of...

Affymetrix Announces Winner Of Anatrace Membrane Protein Award

Affymetrix Announces Winner Of Anatrace Membrane Protein Award

Affymetrix, Inc. (Nasdaq: AFFX) today announced that Professor Tom Rapoport of Harvard Medical School and Howard Hughes Medical Institute is the winner of the 2010 Anatrace Membrane Protein Award.

Affymetrix, Joe's Jeans: Early Volume Plays

Affymetrix, Joe's Jeans: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.

MDRNA, Affymetrix: Early Volume Plays

MDRNA, Affymetrix: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Merck: Analysts' Upgrades, Downgrades

Merck: Analysts' Upgrades, Downgrades

Merck is upgraded at Credit Suisse to Outperform from Neutral.

Affymetrix Gets Emergency Swine Flu Test Clearance

Affymetrix and TessArrae say FDA grants emergency marketing approval for RM-Flu swine flu test

Xerox, AT&T, Kimberly-Clark Are Big Movers

Xerox, AT&T, Kimberly-Clark, Fifth Third, Amgen are among big market movers Thursday

Affymetrix Tumbles On 3Q Miss And 4Q Revenue View

Affymetrix shares slide; analyst says weak genotyping sales hurt 3rd qtr results and outlook

Affymetrix Posts Smaller 3Q Loss, But Shares Fall

Affymetrix Posts Smaller 3Q Loss, But Shares Fall

Affymetrix reports smaller 3rd-quarter loss, but results miss estimates, shares tumble

Wait for Resolution

Keep an eye out for any stocks or sectors that are moving their own way. That should be an easy chore.

Key Health Care Senators Have Industry Ties

Influential senators in health care overhaul have ties with some of biggest names in industry

Affymetrix Shares Fall On 1Q Loss

Affymetrix shares fall following report of 1st-quarter loss as revenue plunges

Dionex Names Frank Witney As President And CEO

Dionex appoints Frank Witney of Affymetrix as new president and chief executive

Health Winners & Losers: Amag

Health Winners & Losers: Amag

Optimer is up 17%.

This Week's Barron's Roundup

"Loser" stocks to champion, and why you should pay attention to insider buying right now.

Small-Cap Winners & Losers: Crocs

Small-Cap Winners & Losers: Crocs

Shares of the popular shoemaker, Crocs, shed after reporting softened second-quarter profit and sales outlook, leading to an analyst downgrade.

Stocks Look on Bright Side

Frank Curzio reviews the action with guests Mike Comeau, who discusses Intel, and Larsen Kusick, who waxes on Crocs.

Tuesday's Analysts' Upgrades, Downgrades

Tuesday's Analysts' Upgrades, Downgrades

See who made what calls.